Tinlarebant

Tinlarebant
Identifiers
	IUPAC name 1-[3-[4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl]-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl]ethanone;
CAS Number	1821327-95-0;
PubChem CID	92044505;
DrugBank	DB17832;
ChemSpider	68006872;
UNII	63WI9S8P1M;
KEGG	D12351;
ChEMBL	ChEMBL3967849;
Chemical and physical data
Formula	C21H21F5N4O2
Molar mass	456.417 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)N1CCC2=C(C1)NN=C2C(=O)N3CCC(CC3)C4=C(C(=C(C=C4)F)F)C(F)(F)F;
	InChI InChI=1S/C21H21F5N4O2/c1-11(31)30-9-6-14-16(10-30)27-28-19(14)20(32)29-7-4-12(5-8-29)13-2-3-15(22)18(23)17(13)21(24,25)26/h2-3,12H,4-10H2,1H3,(H,27,28); Key:HAGSLCBZFRRBLS-UHFFFAOYSA-N;

Tinlarebant is a investigational new drug that is being evaluated to treat dry macular degeneration and Stargardt disease.^[1] It is a retinol binding protein 4 antagonist.^[2]

References

^ "Tinlarebant - Belite Bio". AdisInsight. Springer Nature Switzerland AG.
^ Kim N, Priefer R (December 2021). "Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development". European Journal of Medicinal Chemistry. 226: 113856. doi:10.1016/j.ejmech.2021.113856. PMID 34547506.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.